MODELING OF TYPE 2 DIABETES MELLITUS IS A NECESSARY FOUNDATION FOR STUDY OF MEDICINAL PRODUCTS WITH ANTIDIABETIC POTENCY
Taking into account the worldwide increasing number of patients with type 2 diabetes mellitus, the actual problem of modern pharmacology continues to be the development of antidiabetic drugs with high therapeutic activity and having a better risk-benefit profile. In this connection diabetes modeling is very important, it allows reliably detect the presence of a particular pharmacological activity or new components in the mechanism of drugs action. Models of diabetes can be obtained from various species of animals spontaneously, induced by chemical diabetogenic substances, dietary or surgical procedures, or a combination of these methods. This review presents examples of standard, enough studied models of type 2 diabetes mellitus (genetic and nongenetic) that are designed for small laboratory animals (mice, rats), with a brief description of their production and use. It is concluded that the modeling of type 2 diabetes mellitus is a necessary foundation for the pre-clinical study of anti-diabetic drugs, and the use of different models allows a reasonable extrapolation of the experimental data on people suffering from type 2 diabetes mellitus.
G.N.Chukanova1, M. Dworacka2, S.S. Iskakova1, 1Ye.Zh. Kurmambaev
1West-Kazakhstan Marat Ospanov State Medical University, Aktobe, Kazakhstan
2 Karol Marcinkowski Medical University, Poznan, Poland
1. IDF Diabetes Atlas. Sixth edition. - 155p.
2. Ahren B. New strategy in type 2 diabetes tested in clinical trials. Glucagon-like peptide 1 (GLP-1) affects basic caused of the disease// Lakartidningen. — 2005. — 102 (8). — P. 545-549.
3. Ahren B., Pacini G., Foley J., Schweizer A. Improved meal-related (beta)-cell function and insulin sensitivity by the dipeptidyl peptidase-iv inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year // Diabetes Care. — 2005. — 28 (8). — P. 1936-1940.
4. Amori RE, LAU J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. Systemic review and meta-analysis. JAMA.-2007.-298.-P.194-206.
5. Аметов А.С., Пакус Е.Н. Опыт использования ин-кретиномиметиков в лечении больных сахарного диабета 2 типа //Consilium medicum.-2010.-№12.-Т.12.-С.18-22.
6. Шестакова М.В. Лираглутид – первый аналог че-ловеческого глюкагоноподобного пептида-1 для введе-ния один раз в сутки: новый этап в терапии сахарного диабета типа 2 // Consilium medicum. - 2010. - №12.-Т.12. - С. 22-25.
7. Онглиза™ (саксаглиптин) — ингибитор дипепти-дилпептидазы-4: «инкретиновый эффект» и клиническое применение //http://www.eurolab.ua
8. Srinivasan K., Ramarao P. Animal models in type 2 diabetes research: An overview //Indian J Med Res. 2007-125(3). - P. 451-472.
9. Risbud M.V., Bhonde R.R. Models of pancreatic re-generation in diabetes //Diabetes Res Clin Pract. - 2002. - 58. - P. 155-165.
10. Leiter E.H., Prochazka M., Shultz L.D. Effect of immunodeficiency on diabetogenesis in getenocally diabetic (db/db) mice //J.Immunol.-1987. - 138. - P. 3224-3229.
11. Goto Y., Kakizaki M., Masaki N. Spontaneous dia-betes produced by selective breeding of normal Wistar rats //Proc. Jpn. Cad.-1975.-51.-P. 80-85.
12. Kawano K., Hirashima T., Mori S. et al. A new rat strain with non-insulin dependent diabetes mellitus, «OLITF» /Rat. News Lett.-1991.-25.-P. 24-25.
13. Chatzigeorgiou A., Halapas A., Kalafatakis K., Kamper E. The use of animal models in the study of diabetes mellitus // In Vivo. – 2009. - 23(2). - P. 245-258.
14. Islam MS, Loots du T. Experimental rodent models of type 2 diabetes: a review // Methods Find Exp Clin Phar-macol. - 2009.-31(4). - P. 249-261.
15. Спасов А.А., Воронкова М.П., Снигур Г.Л., Чепляева Н.И., Чепурнова М.В. Экспериментальная модель сахарного диабета типа 2 // Биомедицина. - 2011. - № 3.- C. 12-18.
16. Portha B., Kergoat M. Dynamic of glucose-induced insulin release during the spontaneous remission of strep-tozotocin diabetes induced in the newborn rat // Diabetes.-1985.-34.- P. 547-579.
17. Bobkiewicz-Kozłowska T., Dworacka M., Kuczyński S. et al. Hypoglycaemic effect of quinolizidine alkaloids — lupanine and 2-thionosparteine on non-diabetic and strep-tozotocin-induced diabetic rats // European Journal of Pharmacology -2007.- 565.- P. 240–244
18. Bonnevie-Nielsen, V., Steffes, M.W., Lernmark, A. A major loss in islet mass and B-cell function precedes hyper-glycemia in mice given multiple low doses of streptozotocin. Diabetes. - 1981. - 30. - P. 424–429.
19. Novelli M., Barbera M., Fierabracci V. et al. Effect of the age and dexamethasone treatment on insulin secretion from isolated perfused rat pancreas // Diabetol. - 1996. - 1. - P. A124
20. Masiello P., Broca C., Gross R. et al. Development of a new model in adult rats administrated streptozotocin and nicotinamide // Diabetes. - 1998. - 47 (2). - P. 224-229.
21. Islam MS, Wilson RD. Experimentally induced rodent models of type 2 diabetes // Methods Mol Biol. - 2012.-933. - P.161-174.
22. Buren J., Ereksson J. Dexamethasone decreases GLUT 1 and GLUT 4 content in primary cultured rat adipo-cytes // Diabetol. - 1999. - 42(1). - P. A170.
23. Fabregat M., Fernandez-Alvarez J., Franco C. et al. Dexamethasone-induced changes in FAD-glycerophosphate degydrogenase expression in human pancreas islets // Diabetol. - 1999. - 42(1). - P. A141.
24. Tanaka S, Hayashi T, Toyoda T, et al. High-fat diet impairs the effects of a single bout of endurance exercise on glucose transport and insulin sensitivity in rat skeletal muscle // Metabolism. - 2007. - 56(12). - P. 1719–1728.
25. Zhao S, Chu Y, Zhang C, et al. Diet-induced central obesity and insulin resistance in rabbits // Journal of Animal Physiology and Animal Nutrition. - 2008. - 92(1). -P. 105–111.
26. Flanagan AM, Brown JL, Santiago CA, Aad PY, Spicer LJ, Spicer MT. High-fat diets promote insulin re-sistance through cytokine gene expression in growing female rats // The Journal of Nutritional Biochemistry. - 2008. - 19(8). - P. 505–513.
27. Reed MJ, Meszaros K, Entes LJ, et al. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat // Metabolism. - 2000. - 49(11). - P. 1390–1394.
28. Srinivasan K., Viswanad B., Asrat L., Kaul CL., Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening // Pharmacol Res. - 2005. - 52(4). - P. 313-320.
29. Sahin K, Onderci M, Tuzcu M, et al. Effect of chro-mium on carbohydrate and lipid metabolism in a rat model of type 2 diabetes mellitus: the fat-fed, streptozotocin-treated rat //Metabolism. - 2007. - 56(9). - P. 1233–1240.
30. Zhang M., Lv XY., Li J., Xu ZG., Chen L. The char-acterization of high-fat diet and multiple low-dose strepto-zotocin induced type 2 diabetes rat model // Exp. Diabetes Res., vol. 2008, Article ID 704045, 9 pages, 2008. Epub 2009 - Jan 4.
Number of Views: 356
Category of articles:
Reviews
Bibliography link
1Г.Н. Чуканова, 2М. Дворацка, 1С.С. Искакова, 1Е.Ж. Курмамбаев МОДЕЛИРОВАНИЕ САХАРНОГО ДИАБЕТА 2 ТИПА ДЛЯ ИЗУЧЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ С АНТИДИАБЕТИЧЕСКОЙ АКТИВНОСТЬЮ //Наука и Здравоохранение 2014.№ 4. С. 4-8 G.N.Chukanova1, M. Dworacka2, S.S. Iskakova1, 1Ye.Zh. Kurmambaev MODELING OF TYPE 2 DIABETES MELLITUS IS A NECESSARY FOUNDATION FOR STUDY OF MEDICINAL PRODUCTS WITH ANTIDIABETIC POTENCY // Nauka i Zdravookhranenie. 2014.№ 4. С. 4-8 Г.Н. Чуканова1, М. Дворацка2, С.С. Ысқақова1, Е.Ж. Кұрмамбаев1 ҚАНТ ДИАБЕТІНІҢ 2 ТИПІН МОДЕЛЬДЕУ- АНТИДИАБЕТТІК БЕЛСЕНДІЛІГІ БАР ЕМДІК ДӘРІ-ДӘРМЕКТЕРДІ ЗЕРТТЕУДЕГІ ҚАЖЕТТІЛІКТІҢ НЕГІЗІ // Ғылым және Денсаулық сақтау 2014.№ 4. С. 4-8Related publications:
INTERRELATION OF INTRAABDOMINAL HYPERTENSION AND MARKERS OF GASTROINTESTINAL TRACT INJURY IN PATIENTS WITH MULTIORGAN DYSFUNCTION
DRUG-INDUCED LIVER INJURY AND GENDER DIFFERENCES
QUALITY OF LIFE IN PRIMARY BILIARY CHOLANGITIS AND ITS ASSESSMENT
DIAGNOSTIC AND THERAPEUTIC LAPAROSCOPY FOR ABDOMINAL INJURIES. REVIEW
METHODS FOR SCHOOL-AGE CHILDREN NUTRITIONAL STATUS ASSESSMENT: FOCUS ON ANTHROPOMETRIC PARAMETERS. A REVIEW.